The founder and chairwoman of India’s biggest biopharma company has made a pledge to offer recombinant human insulin for less than $0.10 per day in low- and middle-income countries (LMICs).
Biocon’s (NSE: BIOCON) Kiran Mazumdar-Shaw made the announcement on Wednesday at a United Nations General Assembly (UNGA) side meeting on innovation and universal health access convened by UNAIDS Health Innovation Exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze